192 Clinicopathologic, genomic and immunophenotypic features and outcomes to immune checkpoint inhibitors in patients with mucinous lung adenocarcinoma

• Mizuki Nishino,
• Biagio Ricciuti,
• Scott J Rodig,
• Joao V Alessi,
• Jia Luo,
• Mark M Awad,
• Bruce E Johnson,
• Federica Pecci,
• Alessandro Di Federico,
• Malini M Gandhi,
• Lynette M Sholl,
• Maisam Makarem,
• Emma Voligny,
• Tom Nguyen,
• Danielle Haradon

Affiliations

Mizuki Nishino

Harvard Medical School, Boston, Massachusetts, USA

Biagio Ricciuti

1Dana-Farber Cancer Institute, Boston, MA, USA

Scott J Rodig

2Brigham and Women’s Hospital, Boston, MA, USA

Joao V Alessi

1Dana-Farber Cancer Institute, Boston, MA, USA

Jia Luo

The Department of Clinical Psychology, Beijing Anding Hospital, Capital Medical University, Beijing, China

Mark M Awad

2Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Bruce E Johnson

1Dana-Farber Cancer Institute, Boston, MA, USA

Federica Pecci

1Dana-Farber Cancer Institute, Boston, MA, USA

Alessandro Di Federico

1Dana-Farber Cancer Institute, Boston, MA, USA

Malini M Gandhi

1Dana-Farber Cancer Institute, Boston, MA, USA

Lynette M Sholl

12Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

Maisam Makarem

2Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Emma Voligny

2Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Tom Nguyen

2Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Danielle Haradon

2Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA